DK168763B1 - Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling - Google Patents

Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling Download PDF

Info

Publication number: DK168763B1
Authority: DK; Denmark
Prior art keywords: compound; formula; phenoxy; benzene ring; piperidinomethyl
Prior art date: 1984-11-03

Application number

DK500985A

Other languages

Danish (da)

English (en)

Other versions

DK500985D0 (da

DK500985A (da

Inventor

Rodney Christopher Young

Ian Ross Smith

Thomas Henry Brown

Robert Christopher Mitchell

Original Assignee

Smith Kline French Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-11-03

Filing date

1985-10-31

Publication date

1994-06-06

1984-11-03 Priority claimed from GB848427878A external-priority patent/GB8427878D0/en

1985-07-13 Priority claimed from GB858517714A external-priority patent/GB8517714D0/en

1985-10-31 Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab

1985-10-31 Publication of DK500985D0 publication Critical patent/DK500985D0/da

1986-05-04 Publication of DK500985A publication Critical patent/DK500985A/da

1994-06-06 Application granted granted Critical

1994-06-06 Publication of DK168763B1 publication Critical patent/DK168763B1/da

Links

238000002360 preparation method Methods 0.000 title claims abstract description 22
238000000034 method Methods 0.000 title claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
230000001404 mediated effect Effects 0.000 title abstract description 10
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title description 80
229960001340 histamine Drugs 0.000 title description 40
210000004556 brain Anatomy 0.000 title description 19
125000000623 heterocyclic group Chemical group 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 210
-1 pyrrolidino, piperidino Chemical group 0.000 claims abstract description 50
150000003839 salts Chemical class 0.000 claims abstract description 29
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 5
230000008569 process Effects 0.000 claims abstract description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 34
125000000217 alkyl group Chemical group 0.000 claims description 33
239000001257 hydrogen Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
229910052736 halogen Inorganic materials 0.000 claims description 22
150000002367 halogens Chemical class 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 21
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
125000006308 propyl amino group Chemical group 0.000 claims description 21
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 20
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
238000006243 chemical reaction Methods 0.000 claims description 17
229910052760 oxygen Inorganic materials 0.000 claims description 13
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
239000001301 oxygen Substances 0.000 claims description 12
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 10
150000001555 benzenes Chemical group 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 6
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical class NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000002243 precursor Substances 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
231100000869 headache Toxicity 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 5
101100134927 Gallus gallus COR8 gene Proteins 0.000 claims 1
150000001721 carbon Chemical group 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract description 11
230000008499 blood brain barrier function Effects 0.000 abstract description 9
210000001218 blood-brain barrier Anatomy 0.000 abstract description 9
102000003710 Histamine H2 Receptors Human genes 0.000 abstract description 8
108090000050 Histamine H2 Receptors Proteins 0.000 abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 6
239000005557 antagonist Substances 0.000 abstract description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract description 2
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
NCPBPWTXQHCWFD-UHFFFAOYSA-N 1,3-benzothiazole;1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1.C1=CC=C2SC=NC2=C1 NCPBPWTXQHCWFD-UHFFFAOYSA-N 0.000 abstract 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
150000002460 imidazoles Chemical class 0.000 abstract 1
150000003222 pyridines Chemical class 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 84
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 82
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 36
239000003921 oil Substances 0.000 description 33
235000019198 oils Nutrition 0.000 description 33
239000000243 solution Substances 0.000 description 30
235000019441 ethanol Nutrition 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 27
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
230000002829 reductive effect Effects 0.000 description 22
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
238000004440 column chromatography Methods 0.000 description 19
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
239000000377 silicon dioxide Substances 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 16
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 15
239000011976 maleic acid Substances 0.000 description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 14
239000003480 eluent Substances 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 14
239000007787 solid Substances 0.000 description 13
230000000694 effects Effects 0.000 description 12
VQSXCZMVUMSITD-UHFFFAOYSA-N 3-[3-(piperidin-1-ylmethyl)phenoxy]propan-1-amine Chemical compound NCCCOC1=CC=CC(CN2CCCCC2)=C1 VQSXCZMVUMSITD-UHFFFAOYSA-N 0.000 description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
239000000460 chlorine Substances 0.000 description 10
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
229910052801 chlorine Inorganic materials 0.000 description 9
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
239000000047 product Substances 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
229910052794 bromium Inorganic materials 0.000 description 8
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 7
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 7
102000012740 beta Adrenergic Receptors Human genes 0.000 description 7
108010079452 beta Adrenergic Receptors Proteins 0.000 description 7
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000002026 chloroform extract Substances 0.000 description 7
239000012280 lithium aluminium hydride Substances 0.000 description 7
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
238000010992 reflux Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
229920001202 Inulin Polymers 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
208000005392 Spasm Diseases 0.000 description 4
208000001407 Vascular Headaches Diseases 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
239000001961 anticonvulsive agent Substances 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000012458 free base Substances 0.000 description 4
229940029339 inulin Drugs 0.000 description 4
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
235000006408 oxalic acid Nutrition 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
239000003826 tablet Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
ORGBERFQYFWYGX-UHFFFAOYSA-N 3-(piperidin-1-ylmethyl)phenol Chemical compound OC1=CC=CC(CN2CCCCC2)=C1 ORGBERFQYFWYGX-UHFFFAOYSA-N 0.000 description 3
QETMPAUWGYOIBD-UHFFFAOYSA-N 4,5-dimethyl-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,3-thiazol-2-amine Chemical compound S1C(C)=C(C)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 QETMPAUWGYOIBD-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000000908 ammonium hydroxide Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
229940079593 drug Drugs 0.000 description 3
ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 3
230000027119 gastric acid secretion Effects 0.000 description 3
150000004678 hydrides Chemical class 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000001256 tonic effect Effects 0.000 description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
PDOWLYNSFYZIQX-UHFFFAOYSA-N 2-bromo-3-methoxypyridine Chemical compound COC1=CC=CN=C1Br PDOWLYNSFYZIQX-UHFFFAOYSA-N 0.000 description 2
OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
GBECGCDVAVIEJP-UHFFFAOYSA-N 3-[3-(piperidin-1-ylmethyl)phenoxy]propanoic acid Chemical compound OC(=O)CCOC1=CC=CC(CN2CCCCC2)=C1 GBECGCDVAVIEJP-UHFFFAOYSA-N 0.000 description 2
CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
102000000543 Histamine Receptors Human genes 0.000 description 2
108010002059 Histamine Receptors Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
150000001204 N-oxides Chemical class 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
HTEAHSOWQOLOHK-UHFFFAOYSA-N [O-][N+](=O)C1=CC=[N+]([O-])C(NCCCOC=2C=C(CN3CCCCC3)C=CC=2)=C1 Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(NCCCOC=2C=C(CN3CCCCC3)C=CC=2)=C1 HTEAHSOWQOLOHK-UHFFFAOYSA-N 0.000 description 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
150000001241 acetals Chemical class 0.000 description 2
239000003929 acidic solution Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000010339 dilation Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
229960000582 mepyramine Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
BDGPWBUCDLNNIT-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyridin-3-amine Chemical compound C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=CC=CN=C1 BDGPWBUCDLNNIT-UHFFFAOYSA-N 0.000 description 2
QDMZBAVFZGVYLS-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyrimidin-2-amine Chemical compound C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=NC=CC=N1 QDMZBAVFZGVYLS-UHFFFAOYSA-N 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000033764 rhythmic process Effects 0.000 description 2
210000005245 right atrium Anatomy 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
229940124629 β-receptor antagonist Drugs 0.000 description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
WXOHRQAMBKXWME-UHFFFAOYSA-N 1-methyl-2-methylsulfanylbenzimidazole Chemical compound C1=CC=C2N(C)C(SC)=NC2=C1 WXOHRQAMBKXWME-UHFFFAOYSA-N 0.000 description 1
XOORYPHIZDZJGU-UHFFFAOYSA-N 1-methyl-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 XOORYPHIZDZJGU-UHFFFAOYSA-N 0.000 description 1
VSYAIJANWKDHIV-UHFFFAOYSA-N 1-methylsulfonylisoquinoline Chemical compound C1=CC=C2C(S(=O)(=O)C)=NC=CC2=C1 VSYAIJANWKDHIV-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
FBLQDVYWHQRTGJ-UHFFFAOYSA-N 2-[3-(piperidin-1-ylmethyl)phenoxy]acetonitrile Chemical compound N#CCOC1=CC=CC(CN2CCCCC2)=C1 FBLQDVYWHQRTGJ-UHFFFAOYSA-N 0.000 description 1
HZCYZMOZKBDUHH-UHFFFAOYSA-N 2-[3-(piperidin-1-ylmethyl)phenoxy]ethanamine Chemical compound NCCOC1=CC=CC(CN2CCCCC2)=C1 HZCYZMOZKBDUHH-UHFFFAOYSA-N 0.000 description 1
KFDCCJYUMCYAAA-UHFFFAOYSA-N 2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CCCOC(C=1)=CC=CC=1CN1CCCCC1 KFDCCJYUMCYAAA-UHFFFAOYSA-N 0.000 description 1
XMXLBDNVSIHRRA-UHFFFAOYSA-N 2-amino-4,5-dimethyl-thiazole Natural products CC=1N=C(N)SC=1C XMXLBDNVSIHRRA-UHFFFAOYSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
IRBDHXCXCSFNEQ-UHFFFAOYSA-N 2-bromo-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Br)=C1 IRBDHXCXCSFNEQ-UHFFFAOYSA-N 0.000 description 1
KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 1
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 1
QFFQGCQTQZRSIB-UHFFFAOYSA-N 2-chloro-2-ethoxy-1H-quinoline Chemical compound ClC1(NC2=CC=CC=C2C=C1)OCC QFFQGCQTQZRSIB-UHFFFAOYSA-N 0.000 description 1
YSTCMHHKDOVZDA-UHFFFAOYSA-N 2-chloro-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1 YSTCMHHKDOVZDA-UHFFFAOYSA-N 0.000 description 1
XODBBWCMOHPBMI-UHFFFAOYSA-N 2-chloro-5,6-dimethyl-1,3-benzothiazole Chemical compound C1=C(C)C(C)=CC2=C1SC(Cl)=N2 XODBBWCMOHPBMI-UHFFFAOYSA-N 0.000 description 1
UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
FFWUFQSTCKBEBE-UHFFFAOYSA-N 3-[3-(piperidin-1-ylmethyl)phenoxy]propanenitrile Chemical compound N#CCCOC1=CC=CC(CN2CCCCC2)=C1 FFWUFQSTCKBEBE-UHFFFAOYSA-N 0.000 description 1
RAOUDGXTAZIXBW-UHFFFAOYSA-N 3-[3-(piperidin-1-ylmethyl)phenoxy]propanoyl chloride;hydrochloride Chemical compound Cl.ClC(=O)CCOC1=CC=CC(CN2CCCCC2)=C1 RAOUDGXTAZIXBW-UHFFFAOYSA-N 0.000 description 1
ZEQMMXMSZSMEND-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]phenoxy]propan-1-amine Chemical compound CN(C)CC1=CC=CC(OCCCN)=C1 ZEQMMXMSZSMEND-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OLGXOPAHEYIGSF-UHFFFAOYSA-N 3-chloro-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyridin-2-amine Chemical compound ClC1=CC=CN=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 OLGXOPAHEYIGSF-UHFFFAOYSA-N 0.000 description 1
NWWHGXNIQYJJRY-UHFFFAOYSA-N 3-methoxy-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyridin-2-amine Chemical compound COC1=CC=CN=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 NWWHGXNIQYJJRY-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
XYTUTNQRQLAZLK-UHFFFAOYSA-N 4,5-dimethyl-1,3-thiazol-2-amine;hydrochloride Chemical compound Cl.CC=1N=C(N)SC=1C XYTUTNQRQLAZLK-UHFFFAOYSA-N 0.000 description 1
YSMRPDXIWIIOTG-UHFFFAOYSA-N 4-[3-(piperidin-1-ylmethyl)phenoxy]butan-1-amine Chemical compound NCCCCOC1=CC=CC(CN2CCCCC2)=C1 YSMRPDXIWIIOTG-UHFFFAOYSA-N 0.000 description 1
HSGQGWSJZKKFKE-UHFFFAOYSA-N 4-[3-(piperidin-1-ylmethyl)phenoxy]butanenitrile Chemical compound N#CCCCOC1=CC=CC(CN2CCCCC2)=C1 HSGQGWSJZKKFKE-UHFFFAOYSA-N 0.000 description 1
FTCMXPZFMSVGJO-UHFFFAOYSA-N 4-ethoxy-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]quinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(OCC)=CC=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 FTCMXPZFMSVGJO-UHFFFAOYSA-N 0.000 description 1
FEXIEMAAKBNTFK-UHFFFAOYSA-N 4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC=C1 FEXIEMAAKBNTFK-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
IODWHFFPQHUDAG-UHFFFAOYSA-N 5,6-dimethyl-1,3-benzothiazol-2-amine Chemical compound C1=C(C)C(C)=CC2=C1SC(N)=N2 IODWHFFPQHUDAG-UHFFFAOYSA-N 0.000 description 1
JFDODZZCAYUHIF-UHFFFAOYSA-N 5-[3-(piperidin-1-ylmethyl)phenoxy]pentan-1-amine Chemical compound NCCCCCOC1=CC=CC(CN2CCCCC2)=C1 JFDODZZCAYUHIF-UHFFFAOYSA-N 0.000 description 1
PDOKRLULZKFGMB-UHFFFAOYSA-N 5-[3-(piperidin-1-ylmethyl)phenoxy]pentanenitrile Chemical compound N#CCCCCOC1=CC=CC(CN2CCCCC2)=C1 PDOKRLULZKFGMB-UHFFFAOYSA-N 0.000 description 1
UVCYPXUPCQCCHG-UHFFFAOYSA-N 6-methoxy-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyridin-2-amine Chemical compound COC1=CC=CC(NCCCOC=2C=C(CN3CCCCC3)C=CC=2)=N1 UVCYPXUPCQCCHG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
206010015943 Eye inflammation Diseases 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102100029076 Histamine N-methyltransferase Human genes 0.000 description 1
108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
108010014095 Histidine decarboxylase Proteins 0.000 description 1
102100037095 Histidine decarboxylase Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
KUBONGDXTUOOLM-UHFFFAOYSA-N N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 KUBONGDXTUOOLM-UHFFFAOYSA-N 0.000 description 1
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
IAMCDQSPTSYYHL-UHFFFAOYSA-N OC(=O)C(O)=O.OC(=O)C(O)=O.C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=NC=CC=N1 Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O.C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=NC=CC=N1 IAMCDQSPTSYYHL-UHFFFAOYSA-N 0.000 description 1
MUMYEQMVTGJQFQ-UHFFFAOYSA-N OC(=O)C(O)=O.OC(=O)C(O)=O.ClC1=CC=CN=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O.ClC1=CC=CN=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 MUMYEQMVTGJQFQ-UHFFFAOYSA-N 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042220 Stress ulcer Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
238000005273 aeration Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
125000006309 butyl amino group Chemical group 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940045803 cuprous chloride Drugs 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000004406 elevated intraocular pressure Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
VIASCVHAGATDQI-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,3-benzoxazol-2-amine Chemical compound N=1C2=CC=CC=C2OC=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 VIASCVHAGATDQI-UHFFFAOYSA-N 0.000 description 1
KHOCPPWRDKJTNB-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,3-thiazol-2-amine Chemical compound C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=NC=CS1 KHOCPPWRDKJTNB-UHFFFAOYSA-N 0.000 description 1
XPCMNSYBNUQRGU-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=NC=CS1 XPCMNSYBNUQRGU-UHFFFAOYSA-N 0.000 description 1
YLLDMFNSWIGNPW-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]pyridin-2-amine Chemical compound C=1C=CC(CN2CCCCC2)=CC=1OCCCNC1=CC=CC=N1 YLLDMFNSWIGNPW-UHFFFAOYSA-N 0.000 description 1
HFMTYVWVUHPBEP-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]quinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 HFMTYVWVUHPBEP-UHFFFAOYSA-N 0.000 description 1
QCWIRVUKKYVUGF-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]quinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 QCWIRVUKKYVUGF-UHFFFAOYSA-N 0.000 description 1
GINQQJVBDSYOOM-UHFFFAOYSA-N n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]quinolin-4-amine Chemical compound C=1C=NC2=CC=CC=C2C=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 GINQQJVBDSYOOM-UHFFFAOYSA-N 0.000 description 1
NRUMIJQKAMYLJI-UHFFFAOYSA-N n-[3-[3-(pyrrolidin-1-ylmethyl)phenoxy]propyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCOC(C=1)=CC=CC=1CN1CCCC1 NRUMIJQKAMYLJI-UHFFFAOYSA-N 0.000 description 1
OKJQVDSANNGVOS-UHFFFAOYSA-N n-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1,3-benzothiazol-2-amine Chemical compound CN(C)CC1=CC=CC(OCCCNC=2SC3=CC=CC=C3N=2)=C1 OKJQVDSANNGVOS-UHFFFAOYSA-N 0.000 description 1
DGASKSUJTPFZEM-UHFFFAOYSA-N n-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1,3-benzothiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.CN(C)CC1=CC=CC(OCCCNC=2SC3=CC=CC=C3N=2)=C1 DGASKSUJTPFZEM-UHFFFAOYSA-N 0.000 description 1
VDYYWPHBEADYNJ-UHFFFAOYSA-N n-[4-[3-(piperidin-1-ylmethyl)phenoxy]butyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCCOC(C=1)=CC=CC=1CN1CCCCC1 VDYYWPHBEADYNJ-UHFFFAOYSA-N 0.000 description 1
YWPICNNCEVAMCX-UHFFFAOYSA-N n-[5-[3-(piperidin-1-ylmethyl)phenoxy]pentyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCCCOC(C=1)=CC=CC=1CN1CCCCC1 YWPICNNCEVAMCX-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007658 neurological function Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229960005152 pentetrazol Drugs 0.000 description 1
125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960002790 phenytoin sodium Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Peptides Or Proteins (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)
Eye Examination Apparatus (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

DK500985A 1984-11-03 1985-10-31 Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling DK168763B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB848427878A GB8427878D0 (en)	1984-11-03	1984-11-03	Compounds
GB8427878		1984-11-03
GB858517714A GB8517714D0 (en)	1985-07-13	1985-07-13	Compounds
GB8517714		1985-07-13

Publications (3)

Publication Number	Publication Date
DK500985D0 DK500985D0 (da)	1985-10-31
DK500985A DK500985A (da)	1986-05-04
DK168763B1 true DK168763B1 (da)	1994-06-06

Family

ID=26288415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK500985A DK168763B1 (da)	1984-11-03	1985-10-31	Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling

Country Status (22)

Country	Link
US (2)	US4681883A (es)
EP (1)	EP0181163B1 (es)
JP (1)	JPH0764816B2 (es)
KR (1)	KR930002490B1 (es)
CN (1)	CN85108132A (es)
AT (1)	ATE48839T1 (es)
AU (1)	AU576269B2 (es)
CA (1)	CA1260468A (es)
DE (1)	DE3574872D1 (es)
DK (1)	DK168763B1 (es)
ES (2)	ES8702385A1 (es)
FI (1)	FI854275A7 (es)
GR (1)	GR852644B (es)
HU (1)	HU194211B (es)
IE (1)	IE58586B1 (es)
IL (1)	IL76871A0 (es)
JO (1)	JO1410B1 (es)
NO (1)	NO164096C (es)
NZ (1)	NZ214023A (es)
PH (1)	PH22679A (es)
PT (1)	PT81405B (es)
ZW (1)	ZW19285A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8417194D0 (en) *	1984-07-05	1984-08-08	Boots Co Plc	Therapeutic agents
US5206149A (en) *	1989-04-28	1993-04-27	Toray Industries, Inc.	Method of high sensitivity luminescence analysis
US5451596A (en) *	1992-12-29	1995-09-19	Rhone Poulenc Rorer Pharmaceuticals Inc.	Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5434163A (en) *	1993-05-14	1995-07-18	The Medical College Of Pennsylvania	Treatment of Cryptococcus neoformans infection
US5455260A (en) *	1993-05-21	1995-10-03	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aliphatic amino bis-aryl squalene synthase inhibitors
AU1117497A (en) *	1995-11-13	1997-06-05	Albany Medical College	Analgesic compounds and uses thereof
DE19645313A1 (de)	1996-11-04	1998-05-07	Basf Ag	Substituierte 3-Benzylpyrazole
EP2111223A4 (en) *	2007-11-01	2012-08-15	Acucela Inc	AMINO-DERIVED COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
EP3035926B1 (en)	2013-08-19	2020-07-29	The Regents of The University of California	Compounds and methods for treating an epileptic disorder
EP4196793A1 (en)	2020-08-11	2023-06-21	Université de Strasbourg	H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA793443B (en) *	1978-07-26	1980-12-31	Glaxo Group Ltd	Heterocyclic derivatives
US4496567A (en) *	1978-11-13	1985-01-29	Smith Kline & French Laboratories Limited	Phenyl alkylaminopyrimidones
US4521418A (en) *	1979-02-21	1985-06-04	Smith Kline & French Laboratories Limited	Guanidinothiazolyl derivatives
JPS5775975A (en) *	1980-08-27	1982-05-12	Glaxo Group Ltd	Heterocyclic derivative, manufacture and medicinal composition containing same
US4439437A (en) *	1981-04-28	1984-03-27	Smith Kline & French Laboratories Limited	2-[2-Thiazolyl or 2-guanidino-4-thiazolyl methylthioethyl(or butyl)amino]-3-(hydroxy or carboxy)pyridines, compositions containing same and method of use
US4447611A (en) *	1982-05-27	1984-05-08	American Home Products Corporation	Benzo-fused and heterocyclic fused imidazole anti-ulcer agents
US4490527A (en) *	1982-09-30	1984-12-25	American Home Products Corporation	Benzo-fused heterocyclic anti-ulcer agents
GB8318638D0 (en) *	1983-07-09	1983-08-10	Smith Kline French Lab	Chemical compounds
GB8332091D0 (en) *	1983-12-01	1984-01-11	Smith Kline French Lab	Chemical compounds
GB8417194D0 (en) *	1984-07-05	1984-08-08	Boots Co Plc	Therapeutic agents
CA1272483A (en) *	1985-03-14	1990-08-07	Ube Industries Limited	Phenoxyalkylaminopyrimidine derivatives, their preparation and insecticidal and acaricidal compositions containing them

1985
- 1985-10-14 JO JO19851410A patent/JO1410B1/en active
- 1985-10-17 US US06/788,261 patent/US4681883A/en not_active Expired - Fee Related
- 1985-10-28 CA CA000493967A patent/CA1260468A/en not_active Expired
- 1985-10-28 PH PH32986A patent/PH22679A/en unknown
- 1985-10-28 AU AU49113/85A patent/AU576269B2/en not_active Ceased
- 1985-10-29 IL IL76871A patent/IL76871A0/xx not_active IP Right Cessation
- 1985-10-30 PT PT81405A patent/PT81405B/pt not_active IP Right Cessation
- 1985-10-30 ZW ZW192/85A patent/ZW19285A1/xx unknown
- 1985-10-31 FI FI854275A patent/FI854275A7/fi not_active Application Discontinuation
- 1985-10-31 NZ NZ214023A patent/NZ214023A/xx unknown
- 1985-10-31 DK DK500985A patent/DK168763B1/da not_active IP Right Cessation
- 1985-10-31 ES ES548448A patent/ES8702385A1/es not_active Expired
- 1985-10-31 AT AT85307929T patent/ATE48839T1/de not_active IP Right Cessation
- 1985-10-31 DE DE8585307929T patent/DE3574872D1/de not_active Expired - Lifetime
- 1985-10-31 EP EP85307929A patent/EP0181163B1/en not_active Expired
- 1985-11-01 KR KR1019850008130A patent/KR930002490B1/ko not_active Expired - Fee Related
- 1985-11-01 HU HU854203A patent/HU194211B/hu unknown
- 1985-11-01 NO NO854368A patent/NO164096C/no unknown
- 1985-11-01 IE IE268385A patent/IE58586B1/en not_active IP Right Cessation
- 1985-11-02 CN CN198585108132A patent/CN85108132A/zh active Pending
- 1985-11-04 GR GR852644A patent/GR852644B/el unknown
- 1985-11-05 JP JP60248670A patent/JPH0764816B2/ja not_active Expired - Lifetime
1986
- 1986-05-16 ES ES555013A patent/ES8706643A1/es not_active Expired
1987
- 1987-06-03 US US07/057,470 patent/US4952589A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA1260468A (en)	1989-09-26
CN85108132A (zh)	1986-07-16
DK500985D0 (da)	1985-10-31
NZ214023A (en)	1989-08-29
PH22679A (en)	1988-11-14
EP0181163A2 (en)	1986-05-14
ES555013A0 (es)	1987-07-01
FI854275A7 (fi)	1986-05-04
HU194211B (en)	1988-01-28
GR852644B (es)	1986-03-05
PT81405B (pt)	1988-02-17
DK500985A (da)	1986-05-04
ES8706643A1 (es)	1987-07-01
NO164096B (no)	1990-05-21
ATE48839T1 (de)	1990-01-15
ES8702385A1 (es)	1987-01-01
NO164096C (no)	1990-08-29
KR860004053A (ko)	1986-06-16
JO1410B1 (en)	1986-11-30
US4681883A (en)	1987-07-21
IE852683L (en)	1986-05-03
EP0181163A3 (en)	1987-02-25
NO854368L (no)	1986-05-05
HUT38926A (en)	1986-07-28
KR930002490B1 (ko)	1993-04-02
US4952589A (en)	1990-08-28
AU4911385A (en)	1986-05-08
FI854275A0 (fi)	1985-10-31
IE58586B1 (en)	1993-10-06
JPH0764816B2 (ja)	1995-07-12
IL76871A0 (en)	1986-02-28
AU576269B2 (en)	1988-08-18
ZW19285A1 (en)	1986-05-21
PT81405A (en)	1985-11-01
JPS61115069A (ja)	1986-06-02
ES548448A0 (es)	1987-01-01
EP0181163B1 (en)	1989-12-20
DE3574872D1 (de)	1990-01-25

Publication	Publication Date	Title
US4806536A (en)	1989-02-21	Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents
JPH0478628B2 (es)	1992-12-11
KR20240095274A (ko)	2024-06-25	프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도
KR19990063918A (ko)	1999-07-26	5ht2c-수용체 길항제로서의 피리미딘 유도체 및 이를 포함하는 약물
DK168763B1 (da)	1994-06-06	Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling
CS248750B2 (en)	1987-02-12	Production method of the 2-(n-subst.guanidino)-4-heteroarylthiazols
SE455945B (sv)	1988-08-22	Tiazolidinderivat, forfarande for framstellning och farmaceutiska kompositioner derav
US10221169B2 (en)	2019-03-05	Substituted aminothiazoles for the treatment of tuberculosis
EP0112142B1 (en)	1990-06-20	Pyridine derivatives
US4210653A (en)	1980-07-01	Pyridyloxypropanolamines
EA018328B1 (ru)	2013-07-30	Новые гетероциклические соединения в качестве антагонистов метаботропных глутаматных рецепторов 5-го подтипа (мглу5)
US4435396A (en)	1984-03-06	Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor
HUP9901208A2 (hu)	2000-04-28	(R)-5-Bróm-n-(1-etil-4-metil-hexahidro-1H-1,4-diazepin-6-il)-2-metoxi-6-(metil-amino)-3-piridin-karboxamid, eljárás előállítására és ezt a vegyületet tartalmazó gyógyászati készítmény
EP0117345B1 (en)	1990-02-28	Aminopyrimidinones as histamine h2-antagonists
EP0132914B1 (en)	1988-06-08	Imidazolinone derivatives as histamine h2-antagonists
US4608380A (en)	1986-08-26	Substituted aminopyridones having histamine H2 -receptor blocking activity
EP0134096B1 (en)	1989-02-01	Aminopyrimidinone derivatives as histamine h2-antagonists
US4863936A (en)	1989-09-05	3,5-Substituted-2-pyridyl-alkylaminocyclobutenediones having histamine h1 -antagonist activity
US4743609A (en)	1988-05-10	Indole derivatives having gastric and antisecretory and cytoprotective properties, and pharmaceutical preparations containing same
EP0452076B1 (en)	2000-07-19	Thiazole and imidazole derivatives and antiulcer composition containing same
US4336261A (en)	1982-06-22	Aryloxypropanolamines
US4366160A (en)	1982-12-28	Imidazole derivatives
KR19990035973A (ko)	1999-05-25	비치환 및 치환된 ｎ-(피롤-1-일)피리딘아민의 항경련제로서의 용도

Legal Events

Date	Code	Title	Description
1994-06-06	B1	Patent granted (law 1993)
1997-06-16	PBP	Patent lapsed